Sandbox:Preeti: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 7: Line 7:
! colspan="2" rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease
! colspan="2" rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease
! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Etiology
! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Etiology
! colspan="7" rowspan="2" |Clinical manifestations
! colspan="6" rowspan="2" |Clinical manifestations
! colspan="5" align="center" style="background:#4479BA; color: #FFFFFF;" + |Paraclinical findings
! colspan="5" align="center" style="background:#4479BA; color: #FFFFFF;" + |Paraclinical findings
! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Gold standard
! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Gold standard
Line 15: Line 15:
|-
|-
! colspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Symptoms
! colspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Symptoms
! colspan="3" |Signs
! colspan="2" |Signs
! colspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" + |CBC
! colspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" + |CBC
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Immunochemistry
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Immunochemistry
Line 25: Line 25:
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Diarrhea
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Diarrhea
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Mass
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Mass
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hepatosplenomegaly
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Other
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Other
! align="center" style="background:#4479BA; color: #FFFFFF;" + |WBC
! align="center" style="background:#4479BA; color: #FFFFFF;" + |WBC
Line 31: Line 30:
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Plt
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Plt
|-
|-
! colspan="18" align="left" style="background:#4479BA; color: #FFFFFF;" + |HL
! colspan="17" align="left" style="background:#4479BA; color: #FFFFFF;" + |HL
|-
|-
! align="center" style="background:#4479BA; color: #FFFFFF;" + |
! align="center" style="background:#4479BA; color: #FFFFFF;" + |
! colspan="2" align="center" style="background:#DCDCDC;" + |Hodgkin's Lymphoma
! colspan="2" align="center" style="background:#DCDCDC;" + |Hodgkin's Lymphoma
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 51: Line 49:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! colspan="18" align="left" style="background:#4479BA; color: #FFFFFF;" + |NHL
! colspan="17" align="left" style="background:#4479BA; color: #FFFFFF;" + |NHL
|-
|-
! rowspan="12" align="center" style="background:#4479BA; color: #FFFFFF;" + |B Cell Lymphoma
! rowspan="12" align="center" style="background:#4479BA; color: #FFFFFF;" + |B Cell Lymphoma
Line 64: Line 62:
| align="center" style="background:#F5F5F5;" + |–
| align="center" style="background:#F5F5F5;" + |–
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |±
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
* Bleeding
* Bleeding
Line 93: Line 90:
* Painless peripheral adenopathy in the cervical, axillary, inguinal, and/or femoral regions
* Painless peripheral adenopathy in the cervical, axillary, inguinal, and/or femoral regions
* Asymptomatic large abdominal mass
* Asymptomatic large abdominal mass
| align="center" style="background:#F5F5F5;" + | +
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* [[Seizures]]
* [[Seizures]]
Line 128: Line 124:
* Palpable masses in skin, breast, and salivary glands
* Palpable masses in skin, breast, and salivary glands
* Generalized lymphadenopathy
* Generalized lymphadenopathy
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
* Extranodal involvement of GI tract, lungs, and CNS
* Extranodal involvement of GI tract, lungs, and CNS
Line 163: Line 158:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
* Painless rapidly enlarging [[lymph nodes]]
* Painless rapidly enlarging [[lymph nodes]]
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
Line 188: Line 182:
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Diarrhea
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Diarrhea
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Mass
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Mass
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hepatosplenomegaly
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Other
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Other
! align="center" style="background:#4479BA; color: #FFFFFF;" + |WBC
! align="center" style="background:#4479BA; color: #FFFFFF;" + |WBC
Line 217: Line 210:
* Jaw mass
* Jaw mass
* [[Abdominal mass|Abdominal masses]]  
* [[Abdominal mass|Abdominal masses]]  
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* [[Ascites]]
* [[Ascites]]
Line 241: Line 233:
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* Mature B-cell Lymphoma
* Mature B-cell Lymphoma
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 260: Line 251:
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* Mature B-cell Lymphoma
* Mature B-cell Lymphoma
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 281: Line 271:
** Deletion 7q21-32
** Deletion 7q21-32
** Translocations of the CDK6 gene located on 7q21  
** Translocations of the CDK6 gene located on 7q21  
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 308: Line 297:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 332: Line 320:
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* Mature B-cell Lymphoma
* Mature B-cell Lymphoma
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 369: Line 356:
* [[Petechiae]]
* [[Petechiae]]
* [[Splenomegaly]]
* [[Splenomegaly]]
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
Line 400: Line 386:
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* Precursor T-cell Lymphomas
* Precursor T-cell Lymphomas
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 418: Line 403:
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* Mature T-cell Lymphoma
* Mature T-cell Lymphoma
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 436: Line 420:
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* Mature T-cell Lymphoma
* Mature T-cell Lymphoma
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 473: Line 456:
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* Cutaneous manifestations
* Cutaneous manifestations
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 487: Line 469:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
* Mature T-cell Lymphoma
* Mature T-cell Lymphoma
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 505: Line 486:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
* Mature T-cell Lymphoma
* Mature T-cell Lymphoma
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 523: Line 503:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
* Mature T-cell Lymphoma
* Mature T-cell Lymphoma
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 541: Line 520:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
* Mature T-cell Lymphoma
* Mature T-cell Lymphoma
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 559: Line 537:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
* Mature T-cell Lymphoma
* Mature T-cell Lymphoma
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 577: Line 554:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
* Mature T-cell Lymphoma
* Mature T-cell Lymphoma
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |

Revision as of 19:21, 17 January 2019


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Preeti Singh, M.B.B.S.[2]

Category Disease Etiology Clinical manifestations Paraclinical findings Gold standard Associated findings
Lab findings
Symptoms Signs CBC Immunochemistry Histopathology
Constitutional symptoms Rash Abdominal pain Diarrhea Mass Other WBC Hb Plt
HL
Hodgkin's Lymphoma
NHL
B Cell Lymphoma B-lymphoblastic leukemia/lymphoma
  • Precursor B-cell Lymphoma
  • Unknown
  • Inherited mutations of PAX5, ETV6, and TP53
+ Nl to ↓
  • Down syndrome
Follicular lymphoma
  • Mature B-cell Lymphoma
  • Reciprocal translocation t(14;18)
  • Overexpression of BCL2
Only in 20% of patients: + + ±
  • Painless peripheral adenopathy in the cervical, axillary, inguinal, and/or femoral regions
  • Asymptomatic large abdominal mass
Nl to ↓
  • CD21
  • CD23
  • Nodular growth pattern
Lymph node biopsy
  • Most common clinically indolent NHL
  • Peripheral nerve compression
Mantle cell lymphoma
  • Fatigue
  • Night sweats
  • Weight Loss
Abdominal distention
  • Palpable masses in skin, breast, and salivary glands
  • Generalized lymphadenopathy
  • Extranodal involvement of GI tract, lungs, and CNS
  • Mental Retardation
  • Lymphocytosis > 4000/µL
Nl to ↓
  • CD5+
  • B-cell antigen positive
  • Overexpression of Cyclin D1
  • Germinal centers filled by small-to-medium atypical lymphocytes
  • Nodular appearance
Diffuse large B cell lymphoma
  • Mature B-cell Lymphoma
  • 8q24/MYC translocations
  • Hypermutated immunoglobulin genes
  • Mutation of BCL6, MYC, PAX5, PIM1, RhoH /TTFn, TP53 genes
  • Translocations involving c-MYC, BCL6, and IgH gene.
  • Fever
  • Night sweats
  • weight loss
Nl to ↓

Centroblastic

Immunoblastic

  • > 90% immunoblasts
  • Trapezoid shaped large lymphoid cells with significant basophilic cytoplasm

Anaplastic

  • Very large cells with a round, oval, or polygonal shape that may resemble Reed-Sternberg cells
Disease Etiology Constitutional symptoms Rash Abdominal pain Diarrhea Mass Other WBC Hb Plt Immunochemistry Histopathology Gold standard Associated findings
Burkitt lymphoma
  • Mature B-cell Lymphoma
  • Translocation of chromosome 8 myc locus such as:
    • t(8;14)
    • t(2;8)
    • t(8;22)
  • Round and small nucleoli
  • basophilic cytoplasm
  • "Starry-sky pattern"
B cell chronic lymphocytic leukemia/small lymphocytic lymphoma
  • Mature B-cell Lymphoma
Marginal zone lymphoma Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) type
  • Mature B-cell Lymphoma
Splenic marginal zone lymphoma
  • Mature B-cell Lymphoma
  • Clonal rearrangements of the immunoglobulin genes (heavy and light chains)
    • Deletion 7q21-32
    • Translocations of the CDK6 gene located on 7q21
  • Small lymphocytes
  • Transformed blasts
  • Epithelial histocytes
  • Plasmacytic differentiation of neoplastic cells
Nodal marginal zone B-cell lymphoma
  • Mature B-cell Lymphoma
  • Stimulation of antigen receptor by autoantigen and co-stimulatory molecule CD40
+
  • Hemorrhage
  • Dyspepsia
  • Follicular cells in reactive zone
  • Centrocyte like cells in marginal zone lymphoma
  • Chronic infectious conditions or autoimmune processes, such as
    • H pylori gastritis
  • Hashimoto thyroiditis
  • Sjögren syndrome
Lymphoplasmacytic lymphoma (Waldenstrom’s macroglobulinemia)
  • Mature B-cell Lymphoma
Hairy cell leukemia
  • Production of cytokines, such as TNF alpha and IL-2R, provide important stimuli for malignant B cells proliferation in hairy cell leukemia.
    • The p38-MAPK-JNK cascade
    • The MEK-ERK cascade
    • The Phosphatidylinositol 3 kinase (PI3K)-AKT cascade
  • Tartrate-resistant acid phosphatase positive
  • CBC
  • Small cells with "fried egg"-like appearance
  • Well-demarcated thread-like cytoplasmic extensions
  • Clear cytoplasm
  • Central round nucleus
  • Peri-nuclear clearing ("water-clear rim" appearance)
T cell lymphoma Precursor T-cell lymphoblastic leukemia/lymphoma
  • Precursor T-cell Lymphomas
Adult T cell leukemia/lymphoma
  • Mature T-cell Lymphoma
Anaplastic large cell lymphoma
  • Mature T-cell Lymphoma
Cutaneous T-cell lymphoma Mycosis fungoides / Sézary syndrome
  • Cutaneous manifestations
Peripheral T-cell lymphoma Subcutaneous panniculitis-like T-cell lymphoma
  • Mature T-cell Lymphoma
Hepatosplenic gamma-delta T-cell lymphoma
  • Mature T-cell Lymphoma
Enteropathy-type intestinal T-cell lymphoma
  • Mature T-cell Lymphoma
Extranodal T-cell lymphoma, nasal type
  • Mature T-cell Lymphoma
Angioimmunoblastic T-cell lymphoma
  • Mature T-cell Lymphoma
Peripheral T-cell lymphoma, unspecified
  • Mature T-cell Lymphoma